The effect of Lenvatinib in treating liver cancer varies among different patients, and it is mainly used to treat advanced liver cancer. Liver cancer mostly refers to primary liver cancer, of which the most common is hepatocellular liver cancer, which belongs to one of the most common malignant tumors. Lenvatinib belongs to the targeted therapeutic agents, which are suitable for patients with unresectable hepatocellular carcinoma who have not received systemic systemic therapy before. Lenvatinib is a tyrosine kinase receptor inhibitor that inhibits the kinase activity of the `vascular endothelial growth factor (VEGF) receptor’, in addition to other tyrosine kinases associated with pro-angiogenic and tumorigenic pathways. Lenvatinib inhibits human endothelial cell proliferation, angiogenesis, and the VEGF signaling pathway, and has anti-tumor neoangiogenesis effects. The global multicenter clinical phase III controlled study showed that the median progression-free survival time of the lenvatinib group was significantly better than that of the sorafenib group, and the risk of disease progression decreased by 34%. Common adverse reactions in the lenvatinib group were hypertension, proteinuria, diarrhea, decreased appetite, fatigue, and hand-foot syndrome. If liver cancer is suspected or diagnosed, it is recommended to go to a regular hospital to evaluate the condition and follow the doctor’s instructions to cooperate with the treatment, so as to avoid delaying the condition. Please strictly follow the doctor’s prescription for medication, and do not use medication on your own.